Home / Insurance / Does Aetna Cover Semaglutide? Insurance Guide 2026
MC
Reviewed by Marcus Chen Updated February 20, 2026

Does Aetna Cover Semaglutide? Insurance Guide 2026

Semaglutide has transformed diabetes and obesity management, but navigating insurance coverage—especially with Aetna—can be complex. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide (sold as Ozempic®, Wegovy®, and Rybelsus®) is FDA-approved for type 2 diabetes and chronic weight management. However, Aetna’s coverage policies vary based on medical necessity, formulary tier, and prior authorization requirements. This guide breaks down Aetna’s stance on semaglutide in 2026, including cost-sharing, appeals, and alternatives if coverage is denied.

Does Aetna Cover Semaglutide for Diabetes?

Aetna does cover semaglutide for type 2 diabetes under most commercial and Medicare Advantage plans, but coverage depends on the specific formulation. Ozempic (injectable semaglutide) and Rybelsus (oral semaglutide) are typically included on Aetna’s formulary for diabetes management, provided the patient meets clinical criteria. According to Aetna’s 2026 policy, semaglutide is approved as a second-line therapy after metformin failure or as a first-line option for patients with established cardiovascular disease (ASCVD) or high ASCVD risk.

Coverage is contingent on prior authorization, which requires documentation of:

  • HbA1c ≥7.0% despite lifestyle modifications and metformin (or intolerance to metformin).
  • Failure of at least one other antidiabetic agent (e.g., sulfonylureas, DPP-4 inhibitors, or SGLT2 inhibitors).
  • For Rybelsus, proof of inability to tolerate injectable GLP-1 agonists.

Aetna’s Medicare plans follow similar guidelines but may require step therapy (e.g., trying a less expensive GLP-1 agonist like liraglutide first). Patients should verify their plan’s formulary, as some Aetna policies exclude semaglutide for diabetes if the patient has not tried a preferred alternative.

Does Aetna Cover Semaglutide for Weight Loss?

Aetna’s coverage of Wegovy (semaglutide 2.4 mg) for chronic weight management is more restrictive than its diabetes policies. As of 2026, Aetna covers Wegovy only for patients meeting strict criteria, including:

  • BMI ≥30 kg/m² (obesity) or BMI ≥27 kg/m² with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia).
  • Documented failure of a structured weight-loss program (e.g., diet, exercise, behavioral therapy) for at least 6 months.
  • Prior authorization requiring proof of participation in a supervised weight-loss program (e.g., through a registered dietitian or physician-led program).

Aetna does not cover Wegovy for cosmetic weight loss or patients without obesity-related comorbidities. Additionally, some Aetna plans exclude anti-obesity medications entirely, classifying them as non-essential. Patients with Medicare should note that Wegovy is not covered under Part D, as Medicare excludes weight-loss drugs by federal law (though some Medicare Advantage plans may offer limited coverage).

For off-label use (e.g., using Ozempic for weight loss), Aetna will not cover semaglutide unless the patient has concurrent type 2 diabetes. Appeals for off-label use are rarely successful without compelling clinical justification.

How Much Does Semaglutide Cost With Aetna?

The out-of-pocket cost of semaglutide with Aetna varies by plan, formulary tier, and whether the patient has met their deductible. In 2026, most Aetna plans classify semaglutide as a Tier 3 or Tier 4 drug, leading to the following estimated costs:

FormulationAetna Copay (Commercial)Aetna Copay (Medicare Advantage)Cash Price (Without Insurance)
Ozempic$50–$100 per month$47–$100 (after deductible)$900–$1,200 per month
Wegovy$100–$200 per monthRarely covered; $1,300+ if covered$1,300–$1,600 per month
Rybelsus$30–$70 per month$30–$70 (after deductible)$900–$1,100 per month

Factors affecting cost:

  • Deductible status: Patients with high-deductible plans may pay the full cash price until the deductible is met.
  • Copay assistance: Novo Nordisk offers a savings card for Ozempic and Wegovy, reducing copays to $25/month for 12–24 months for eligible commercial insurance patients.
  • Prior authorization: If denied, patients may face the full cash price unless an appeal is successful.
  • Mail-order pharmacies: Aetna’s preferred pharmacies (e.g., CVS Caremark) may offer lower copays for semaglutide.

Patients should use Aetna’s drug cost estimator tool or call member services to confirm their exact copay.

Semaglutide Prior Authorization for Aetna

Aetna requires prior authorization (PA) for all semaglutide formulations, whether for diabetes or weight loss. The PA process ensures the drug is medically necessary and aligns with Aetna’s clinical guidelines. Here’s what prescribers must submit:

For Ozempic/Rybelsus (Diabetes):

  1. Patient’s HbA1c (≥7.0% despite metformin or other agents).
  2. Documentation of failed alternative therapies (e.g., sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors).
  3. Presence of ASCVD or high ASCVD risk (if requesting first-line use).
  4. For Rybelsus: Proof of inability to use injectable GLP-1 agonists (e.g., needle phobia, injection-site reactions).

For Wegovy (Weight Loss):

  1. BMI ≥30 or ≥27 with comorbidity (e.g., hypertension, prediabetes, sleep apnea).
  2. Proof of participation in a 6-month structured weight-loss program (e.g., dietitian notes, exercise logs).
  3. Documentation of weight-loss failure (e.g., <5% total body weight loss with lifestyle changes).
  4. Exclusion of secondary causes of obesity (e.g., hypothyroidism, Cushing’s syndrome).

PA approval timeline: Aetna typically reviews requests within 5–10 business days. If denied, prescribers can submit additional clinical evidence (e.g., lab results, specialist letters) for reconsideration.

How to Get Aetna to Cover Semaglutide

If Aetna initially denies coverage, patients and prescribers can take these steps to improve approval chances:

  1. Ensure Complete Documentation

    • Submit detailed medical records showing failed alternative therapies, HbA1c trends (for diabetes), or weight-loss program participation (for Wegovy).
    • Include specialist letters (e.g., endocrinologist, cardiologist) if the patient has comorbidities like ASCVD or NASH.

  2. Use Aetna’s Preferred Formulary Alternatives First

    • For diabetes: Try liraglutide (Victoza) or dulaglutide (Trulicity) before semaglutide, as Aetna may require step therapy.
    • For weight loss: If Wegovy is denied, prescribers can appeal by showing lack of efficacy or intolerance to other GLP-1 agonists (e.g., liraglutide/Saxenda).

  3. Leverage Clinical Guidelines

    • Cite ADA (American Diabetes Association) or AACE (American Association of Clinical Endocrinologists) guidelines, which recommend GLP-1 agonists like semaglutide for patients with ASCVD or obesity.
    • For weight loss, reference AHA/ACC/TOS guidelines, which support anti-obesity medications for patients with BMI ≥27 and comorbidities.

  4. Appeal with a Peer-to-Peer Review

    • If the initial PA is denied, request a peer-to-peer review with an Aetna medical director. Prescribers can explain why semaglutide is the most appropriate therapy for the patient.

  5. Explore Patient Assistance Programs

    • Novo Nordisk’s NovoCare® program offers free medication for uninsured or underinsured patients meeting income criteria.
    • For commercial insurance patients, the Ozempic/Wegovy savings card can reduce copays to $25/month.

What to Do If Aetna Denies Semaglutide

If Aetna denies semaglutide coverage, patients have three main options:

  1. File an Appeal

    • Internal appeal: Submit a written appeal within 60 days of denial, including:
      • A letter of medical necessity from the prescriber.
      • Additional clinical evidence (e.g., lab results, specialist notes).
      • Peer-reviewed studies supporting semaglutide’s efficacy for the patient’s condition.
    • Aetna must respond within 30 days (7 days for urgent cases).

  2. Request an External Review

    • If the internal appeal fails, patients can request an independent external review through their state’s insurance department. An impartial medical expert will reevaluate the case.

  3. Pay Out of Pocket or Seek Alternatives

    • If appeals fail, patients can:
      • Use Novo Nordisk’s savings card (if commercially insured) to reduce costs.
      • Switch to a less expensive GLP-1 agonist (e.g., liraglutide, dulaglutide) if covered by Aetna.
      • Explore compounding pharmacies (though safety and efficacy may vary).
      • Consider clinical trials for semaglutide (e.g., through ClinicalTrials.gov).

Pro tip: If Aetna denies Wegovy for weight loss, prescribers can sometimes reclassify the indication (e.g., documenting prediabetes or metabolic syndrome) to align with diabetes coverage criteria for Ozempic.

Aetna Alternatives If Semaglutide Is Not Covered

If Aetna denies semaglutide or imposes prohibitive costs, patients can explore these alternatives:

For Diabetes:

  1. Liraglutide (Victoza®)

    • Aetna’s preferred GLP-1 agonist for diabetes, often covered without step therapy.
    • Similar efficacy to semaglutide but requires daily injections.

  2. Dulaglutide (Trulicity®)

    • Weekly injection like Ozempic, often covered by Aetna after metformin failure.
    • Slightly lower HbA1c reduction than semaglutide but better tolerated by some patients.

  3. Exenatide (Bydureon®, Byetta®)

    • Twice-daily or weekly injection, less expensive but less effective than semaglutide.
    • Aetna may require this as a step therapy option.

  4. SGLT2 Inhibitors (e.g., empagliflozin/Jardiance®)

    • Oral alternative with cardiovascular benefits, often covered by Aetna.
    • Does not promote weight loss as effectively as semaglutide.

For Weight Loss:

  1. Liraglutide (Saxenda®)

    • FDA-approved for obesity, but Aetna’s coverage is similar to Wegovy (requires BMI ≥30 or ≥27 with comorbidity).
    • Daily injection, slightly less effective than semaglutide.

  2. Phentermine/Topiramate (Qsymia®)

    • Oral weight-loss medication, often covered by Aetna with prior authorization.
    • Contraindicated in pregnancy and patients with glaucoma or hyperthyroidism.

  3. Bupropion/Naltrexone (Contrave®)

    • Oral option for obesity, covered by some Aetna plans.
    • Lower efficacy than semaglutide but may be suitable for patients with depression.

  4. Lifestyle Modifications + Behavioral Therapy

    • Aetna may cover medically supervised weight-loss programs (e.g., through registered dietitians).
    • Less effective alone but required before approving Wegovy.

For Medicare patients: Since Medicare does not cover weight-loss drugs, alternatives include:

  • Intensive behavioral therapy (covered under Medicare Part B).
  • Bariatric surgery (covered for BMI ≥35 with comorbidities).

Frequently Asked Questions

Does Aetna cover Semaglutide for weight loss?

Aetna covers Wegovy (semaglutide 2.4 mg) for weight loss only if the